30 January 2019 - - German health care company Fresenius Kabi has launched Leucovorin Calcium Injection, USP in United States, the company said.

Leucovorin Calcium Injection, USP is a medication indicated to counteract the toxicity and diminish the effects of impaired methotrexate elimination.

Leucovorin Calcium is also used as a rescue drug after high-dose methotrexate therapy in osteosarcoma, in the treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, and in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.

Fresenius Kabi Leucovorin Calcium Injection, USP is available in 10 mg per mL single-use vials, 100 mg per 10 mL and 500 mg per 50 mL strengths.

This is the only liquid presentation of Leucovorin available in the United States.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

The company is a developer, manufacturer and provider of injected and infused medicines in the United States with special expertise in producing high quality, affordable generic alternatives to more expensive brand-name drugs.

Leucovorin calcium rescue is indicated for intramuscular or intravenous administration after high dose methotrexate therapy in osteosarcoma. Leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent over dosages of folic acid antagonists.

It is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible.

Leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.